U.S. FTC requires Amneal and Impax to divest rights to 10 generic drugs

WASHINGTON (Reuters) - The U.S. Federal Trade Commission said on Friday it would require Impax Laboratories Inc and privately held Amneal Pharmaceuticals LLC to divest rights to 10 generic medications as a condition of their merger.